NTRA logo

Natera Inc. (NTRA)$203.19

Market Cap: 21.40 BCurrency: USD

Research Snapshot

Static fundamentals, valuation context, and investor signals for Natera Inc. (NTRA).

HEALTHCARE
DIAGNOSTICS & RESEARCH
DCF ready

Valuation

186.2x

EV/FCF, 0.5% FCF yield

Quality

-12.2%

ROIC, 4.7% FCF margin

Growth

42.6%

5Y sales (revenue) CAGR

Balance sheet

0.0x

Debt/equity, 3.4x current ratio

Superinvestors

3

Top: Lee Ainslie (2.7%)

Strengths to research

  • Revenue compounded at 42.6% over five years.
  • Debt/equity looks manageable at 0.0x.
  • 3 tracked superinvestors report a position.
  • 10 annual periods are available for trend analysis.

Watchouts

  • P/FCF is elevated at 196.1x.
Annual data: 10 periods
Quarterly data: 24 periods
Stock snapshot: May 25, 2026
Static dataset: May 25, 2026

Quality Scorecard

Build-time composite score for NTRA.

Grade F
24
/ 100

Peer Comparison

Target stock against 8 market-cap comparable peers.

Heat map: red worst to green best
NTRA
Target
Natera Inc.$21.4B-133.7x186.2x-12.2%42.6%4.7%N/AN/AN/A
LHLabcorp Holdings Inc.$20.7B24.8x16.7x10.2%-0.0%8.6%28.8%-0.3xN/A
MTDMettler-Toledo International Inc.$22.7B26.2x29.2x42.1%5.5%21.1%59.4%N/AN/A
DGXQuest Diagnostics$19.8B22.3x18.5x7.7%3.2%12.3%N/A2.5xN/A
IQVIQVIA Holdings Inc.$26.9B21.4x12.1x20.9%7.5%12.6%N/A-0.6xN/A
AAgilent Technologies$30.9B25.2x27.9x13.3%5.4%16.6%N/A0.7xN/A
ILMNIllumina Inc.$12.4B26.5x11.8x31.2%6.0%21.4%66.1%-1.3xN/A
IDXXIDEXX Laboratories$38.2B42.8x36.4x51.5%9.7%24.6%61.8%0.2xN/A
ERFSFEurofins Scientific SE$11.5BN/AN/AN/AN/AN/AN/AN/AN/A

Financial Charts

No financial data available for NTRA (annual).

3 superinvestors own NTRA

Current quarter ownership and quarter-over-quarter share changes.

Superinvestor ownership
FundSharesValue% PortfolioQoQ Change
Lee Ainslie

Maverick Capital

1,171,633$234M2.72%0.0%
Torray Funds

Torray Funds

9,569$2M0.30%0.0%
Polen Capital Management

Polen Capital Management

1,269$254,0000.00%0.0%